Anavex Life Sciences Corp (AVXL)

[cninc]

yes, been following them for about a year and they have a lot of preclinical data that looks good. Their MOA is unlike any other drug company. NVG-291 has shown in rat models that it can modulate the PTPsigma receptor and allow nerves to repair themselves and regrow new connections. Lots of promise for AZ, MS and spinal cord injury. All 3 which they are going into trial beginning in 2022. Dr. Jeffrey Cummings is also on the advisor board. Still a small, not well know company since it's a small Canadian company, but the technology is from Dr Jerry Silver from Case Western University. Looking to uplist on Nasdaq sometime in the future as well.